189 related articles for article (PubMed ID: 22125118)
1. Role of C-reactive protein when prescribing a statin.
Kinlay S
Curr Atheroscler Rep; 2012 Feb; 14(1):26-32. PubMed ID: 22125118
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein and cardiovascular diseases--is it ready for primetime?
Lavie CJ; Milani RV; Verma A; O'Keefe JH
Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
[TBL] [Abstract][Full Text] [Related]
4. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options to further lower C-reactive protein for patients on statin treatment.
Joshi PH; Jacobson TA
Curr Atheroscler Rep; 2010 Jan; 12(1):34-42. PubMed ID: 20425269
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis.
Mann DM; Shimbo D; Cushman M; Lakoski S; Greenland P; Blumenthal RS; Michos ED; Lloyd-Jones DM; Muntner P
Clin Cardiol; 2013 Jan; 36(1):15-20. PubMed ID: 22886783
[TBL] [Abstract][Full Text] [Related]
8. Impact of C-reactive protein on treatment of patients with cardiovascular disease.
Gortney JS; Sanders RM
Am J Health Syst Pharm; 2007 Oct; 64(19):2009-16. PubMed ID: 17893410
[TBL] [Abstract][Full Text] [Related]
9. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
10. Should we measure C-reactive protein on earth or just on JUPITER?
Bajpai A; Goyal A; Sperling L
Clin Cardiol; 2010 Apr; 33(4):190-8. PubMed ID: 20394038
[TBL] [Abstract][Full Text] [Related]
11. Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?
Devaraj S; Siegel D; Jialal I
Curr Atheroscler Rep; 2011 Feb; 13(1):31-42. PubMed ID: 21046291
[TBL] [Abstract][Full Text] [Related]
12. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of dietary portfolio vs statin on C-reactive protein.
Jenkins DJ; Kendall CW; Marchie A; Faulkner DA; Josse AR; Wong JM; de Souza R; Emam A; Parker TL; Li TJ; Josse RG; Leiter LA; Singer W; Connelly PW
Eur J Clin Nutr; 2005 Jul; 59(7):851-60. PubMed ID: 15900306
[TBL] [Abstract][Full Text] [Related]
14. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Scheen AJ
Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
[TBL] [Abstract][Full Text] [Related]
16. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
Albert MA; Danielson E; Rifai N; Ridker PM;
JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
[TBL] [Abstract][Full Text] [Related]
17. Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.
Savarese G; Rosano GM; Parente A; D'Amore C; Reiner MF; Camici GG; Trimarco B; Perrone-Filardi P
Int J Cardiol; 2014 Nov; 177(1):152-60. PubMed ID: 25499365
[TBL] [Abstract][Full Text] [Related]
18. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
19. JUPITER study highlights C-reactive protein as a cardiac risk factor.
Cardiovasc J Afr; 2009; 20(2):146. PubMed ID: 19421655
[No Abstract] [Full Text] [Related]
20. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
